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The oncogenic	transcription	factor	Activator	Protein-1	(AP-1)	is	a	DNA	binding	protein	that	
assembles	through	dimerization	of	Fos	and	Jun	protein	subunits,	their	leucine-rich	helical	
sequences	 entwining	 into	 a	 coiled	 coil	 structure.	 This	 study	 reports	 on	 downsizing	 the	
protooncogene	cFos	protein	(380	residues)	to	shorter	peptides	(37-25	residues),	modified	
with	helix-inducing	constraints	to	enhance	binding	to	Jun.	A	crystal	structure	is	reported	
for	 a	 37-residue	 Fos-derived	 peptide	 (FosW)	 bound	 to	 Jun.	 This	 guided	 iterative	
downsizing	of	FosW	to	shorter	peptide	sequences,	constrained	 into	stable	water-soluble	
alpha	 helices	 by	 connecting	 amino	 acid	 sidechains	 to	 form	 cyclic	 pentapeptide	
components.	 Structural	 integrity	 in	 the	 presence	 and	 absence	 of	 Jun	 was	 assessed	 by	
circular	dichroism	spectroscopy,	while	thermodynamics	of	binding	to	cFos	was	measured	
by	 isothermal	 titration	 calorimetry.	 A	 25-residue	 constrained	 peptide,	 one-third	 shorter	
yet	25	%	more	helical	than	the	structurally	characterised	37-residue	Fos-derived	peptide,	
retained	 80	%	of	 the	binding	 free	 energy	 due	 to	 pre-organisation	 in	 a	 Jun-binding	helix	
conformation,	with	entropy	gain	 (TΔS	=	+	3.2	kcal/mol)	 compensating	 for	enthalpy	 loss.	
Attaching	 a	 cell	 penetrating	 peptide	 (TAT48-57)	 and	 a	 nuclear	 localisation	 signal	 (SV40)	
promoted	 cell	 uptake,	 localisation	 to	 the	 nucleus,	 and	 inhibition	 of	 the	 proliferation	 of	
two	breast	cancer	cell	lines.	
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INTRODUCTION	
Most	biological	functions	are	mediated	by	protein-protein	 interactions	(PPIs),	often	
involving	large	protein	surface	areas	and	shallow	binding	interfaces	that	are	not	conducive	
to	 targeting	 with	 conventional	 drug-like	 small	 molecules.	 An	 alternative	 approach	 under	
intensive	investigation	is	to	downsize	one	of	the	interacting	protein	surfaces,	often	a	helix,	
to	 a	 bioactive	 small	 peptide	 capable	 of	 functionally	mimicking	 or	 antagonizing	 the	 PPI	 1.	
Short	peptide	sequences	do	not	form	thermodynamically	stable	helices	in	water.	However,	
amino	acid	variations	based	on	known	α-helical	propensities	2,	together	with	incorporating	
helix	constraints,	can	realise	potent	peptidic	and	peptidomimetic	antagonists	of	PPIs	1,	3,	and	
some	efficacious	 peptides	 have	 entered	 clinical	 trials	 4.	 The	helix	 constraints	 pre-organise	
peptides	 in	 receptor-binding	 α-helical	 conformations	 5,	 with	 improved	 protein-binding	
affinities	 6,	 protease	 resistance	 7-8	 and,	 in	 some	cases,	 increased	 cellular	uptake	 6.	 Lactam	
bridges	have	been	shown	to	be	the	most	effective	constraints	for	inducing	peptide	α-helicity	
9.	Appropriately	placed	constraints	have	been	shown	to	induce	helicity	and	compensate	for	
loss	of	enthalpy	and	binding	free	energy	normally	associated	with	considerable	truncation5.	
They	have	been	used	in	conjunction	with	peptide	truncation	to	derive	small	helical	peptides	
that	penetrate	cell	membranes	10.	Helix	constraints	can	therefore	compensate	for	the	loss	of	
binding	 free	 energy,	 associated	 with	 shortening	 peptide	 sequences,	 by	 pre-organizing	
peptides	 to	 minimize	 the	 entropic	 penalty	 for	 rearranging	 to	 a	 protein-binding	 helical	
conformation	5.	
Activator	Protein-1	 (AP-1)	 is	a	dimeric	 transcription	 factor	 that	 is	hyperactivated	 in	
tumourigenesis	 11-12	 and	 therefore	 antagonism	 of	 its	 function	 represents	 a	 promising	
therapeutic	strategy	for	a	number	of	human	cancers	13.	AP-1	consists	of	different	sub-units	
that	are	assembled	via	a	bZIP	domain.	This	is	composed	of	a	DNA-binding	basic	region	and	a	
‘leucine	zipper’	region	involving	a	supercoiled	heterodimer	region	of	Jun	(cJun,	JunB,	JunD)	
and	 Fos	 (cFos,	 FosB-1	 and	 2,	 Fra-1	 and	 2)	 proteins	 14.	 The	 Jun-Fos	 coiled	 coil	 binding	
interface	 features	 pseudo-parallel	 alignments	 of	 α-helical	 segments	 of	 Jun	 and	 Fos	 that	
make	 contacts	 over	 the	 length	 of	 the	 helices	 15.	 This	 PPI	 is	 difficult	 to	 target	 with	
hydrophobic	drug-like	molecules	due	to	the	lack	of	well-defined	hydrophobic	pockets	16	and	
to	the	difficulty	 in	discriminating	between	the	two	 interacting	helical	segments	of	 Jun	and	
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Fos	proteins.	Small	molecules	examined	to	date	have	lacked	Jun/Fos	specificity	17-18,	which	is	
essential	given	that	some	AP-1	compositions	have	been	shown	to	be	anti-oncogenic	12.	
AP-1	can	be	antagonised	by	cJun	mutants	that	lack	transactivation	domains	19-20,	by	
cJun	and	cFos	mutants	with	truncated	DNA-binding	domains	21,	and	by	mutations	 in	DNA-
binding	 domains	 that	 then	 require	 an	 extended	 dimerisation	 interface	 22.	 These	 mutant	
peptides	bind	efficiently	to	Jun	and,	when	expressed	in	cells,	can	inhibit	AP-1	to	cause	cell	
cycle	arrest	and	reduced	cell	proliferation	22-24.	However,	such	polypeptides	are	susceptible	
to	degradation	by	proteases,	do	not	permeate	cell	membranes,	and	have	low	bioavailability.	
Here	we	 investigate	 the	possibility	of	deriving	 short	helical	peptides	 from	 the	 Jun-binding	
region	of	 cFos,	 a	 protein	 consisting	 of	 380	 amino	 acid	 residues	 featuring	 a	 leucine	 zipper	
region	 for	 heterodimerisation	 with	 Jun,	 a	 basic	 region	 for	 binding	 to	 DNA,	 and	 a	
transactivation	domain	at	its	C-terminus.	We	report	steps	towards	minimising	the	length	of	
the	 Fos	 fragment,	 altering	 it	 using	 helix	 constraints	 to	 optimise	 Fos-Jun	 interactions,	 and	
modifying	the	peptides	further	for	entering	cancer	cells	and	targeting	AP-1	in	the	nucleus	to	
inhibit	proliferation.	This	minimalist	approach	using	helix	constraints	is	still	an	under-utilised	
strategy	 for	 modulating	 protein-protein	 interactions,	 but	 it	 is	 unclear	 whether	 it	 can	 be	
useful	 in	 producing	 effective	 antagonists	 of	 protein-protein	 interactions	 specifically	
involving	coiled	coils	that	tend	to	involve	key	interactions	along	their	entire	interface	25.	
	
RESULTS	
Structure	of	FosW-Jun,	a	model	protein-protein	interface	
We	 have	 previously	 used	 an	 intracellular	 protein-fragment	 complementation	
method	 26	 to	derive	a	37-residue	peptide	FosW	27	 from	a	 cFos-based	 library.	 This	peptide	
was	able	to	bind	Jun	and	antagonise	both	Fos-Jun	and	Jun-Jun	protein-protein	interactions,	
but	 the	 structure	 of	 FosW-Jun	 is	 unknown.	 Here	 we	 have	 complexed	 FosW	 with	 Jun,	
obtained	 diffracting	 crystals,	 and	 determined	 a	 crystal	 structure	 to	 a	 resolution	 of	 2.3	 Å	
(Figure	1	and	Table	S1)	(PDB	ID:	5fv8).	This	is	the	first	crystal	structure	of	an	AP-1	antagonist	
in	complex	with	its	target,	and	importantly	identifies	the	anticipated	binding	mode	of	FosW	
with	Jun	26.	
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Inspection	of	the	crystal	structure	shows	that	FosW	and	Jun	have	bound	together	to	
form	a	parallel	dimeric	coiled	coil,	with	characteristic	hydrophobic	interactions	(ai-a’i	and	di-
d’i)	and	electrostatic	contacts	(gi-e’i+7	and	ei-g’i-7)	(Figure	1	and	Supplementary	Information).	
Consistent	with	other	coiled	coils	 3,	all	 ten	residues	at	positions	a	and	d	are	appropriately	
aligned	 for	 burying	 hydrophobic	 side	 chains	 away	 from	 the	water	 solvent.	 This	 confers	 a	
major	 energy	 contribution	 to	 dimerisation	 28,	 with	 interatomic	 distances	 consistent	 with	
important	structure-stabilising	interhelical	a-a’	and	d-d’	interactions	15,	29.	Thus	our	selection	
of	 predominantly	 bulky	 hydrophobic	 side	 chains	 to	 substitute	 at	 positions	a	 of	 FosW	has	
evidently	 improved	 sidechain	 packing	 in	 the	 core	 relative	 to	 cFos	 residues	 (TΔL,	 TΔI,	 KΔN	
and	KΔL),	thereby	increasing	enthalpy	and	driving	dimerization.	
Interactions	 between	 g1	 E	 and	 e’2	 K,	 and	 g3	 E	 and	 e’4	 R	 are	 potentially	 helix-
stabilising.	Residues	at	g2,	e’3,	e3,	g’2,	e4	and	g’3	are	correctly	positioned	to	make	similar	
interhelical	 interactions,	but	are	too	far	apart	to	form	contacts.	Finally,	an	anticipated	e2–
g’1	E–K	 interaction	 is	not	present	 in	the	crystal	structure;	rather	the	g’1	K	amine	nitrogen	
faces	 away	 from	 the	e2	E.	 The	 crystal	 structure	 indicates	 that	g2	R	 interacts	with	 solvent	
rather	than	with	g3	E.	The	e4	E	does	not	interact	with	g’3	T,	but	may	shield	FosW	a4	I	from	
solvent	with	 its	hydrocarbon	chain.	Similarly,	e1	and	g4	Q	residues,	which	have	no	g’i-7	or	
e’i+7	partner,	shield	a2	I	and	d4	L	core	residues.	Finally,	we	note	that	positions	b,	c	and	f	are	
occupied	by	residues	that	are	not	significantly	involved	in	interhelical	interactions	according	
to	the	crystal	structure,	instead	appearing	to	be	involved	in	solvent	interaction	for	solubility.	
Possible	exceptions	may	be	intrahelical	interactions,	such	as	a	proposed	salt	bridge	between	
f3	K	and	b4	E,	with	attraction	of	f4	K	towards	the	b4	E	and	a	cation–π	attraction	between	b3	
Y	 and	 f3	 K.	 The	 contributions	 of	 these	 intrahelical	 interactions	 to	 α-helix	 adoption	 and	
dimerisation	 free	 energies	 are,	 however,	 expected	 to	 be	 small.	 As	 such,	 FosW	b,	 c	 and	 f	
positions	may	tolerate	replacement	residues	that	form	helix	constraints	without	significantly	
affecting	the	PPI	interface	26.	
	 Jun	 is	predicted	 to	be	a	more	attractive	 target	 than	Fos	because	of	a	more	 typical	
and	hydrophobic	 interface	at	a	and	d	positions	of	the	Jun	heptads	(Figure	1)	compared	to	
the	polar	T/K-containing	Fos	core	 26-27.	As	a	consequence,	Fos	 is	 reported	 to	be	unable	 to	
form	 homodimers,	 and	 requires	 Jun	 family	 members	 to	 form	 transcriptionally	 active	
heterodimers	 30.	 Complexes	 containing	 Jun	 are	 also	 more	 potent	 for	 transcriptional	
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transactivation	 30,	 and	 Jun	 has	 been	 implicated	 in	 a	 number	 of	 cancers	 11-12,	 making	
antagonists	 of	 this	 particular	 homologue	 potentially	 valuable.	 Therefore,	 we	 have	
concentrated	here	on	downsizing	Fos	rather	than	Jun	to	create	antagonists	of	 the	Fos-Jun	
protein-protein	interaction.		
	
Downsizing	FosW	via	helix-inducing	constraints		
The	 major	 aim	 was	 to	 introduce	 one	 or	 more	 helix-inducing	 constraints	 into	 the	
FosW	 sequence	 to	 enable	 downsizing	 of	 the	 molecule	 while	 maintaining	 helicity	 and	
ultimately	affinity	for	cJun.	All	helix-constrained	peptides	lacked	five	residues	that	served	as	
N-terminal	 and	 C-terminal	 capping	motifs	within	 the	 FosW	parent	 peptide.	 This	 led	 us	 to	
iteratively	 examine	 the	 effect	 on	 helix	 induction	 and	 affinity	 using	 one	 or	 more	 such	
constraints	 placed	 at	 different	 positions	 within	 the	 sequence,	 while	 concomitantly	
truncating	 the	 sequence	 from	 either	 terminus	 (see	 Figure	 2	 and	 Supplementary	
Information).	
An	 (iài+4)	 lactam	 bridge	 was	 first	 incorporated	 at	 different	 positions	 along	 the	
sequence	to	learn	which	heptad	regions	were	most	amenable	to	modification	with	a	helix-
inducing	constraint.	This	was	achieved	by	cross-linking	two	amino	acid	residues	at	positions	
shown	 to	 have	 minimal	 involvement	 in	 Fos-Jun	 interhelical	 interactions	 in	 the	 crystal	
structure,	namely	b-to-f	or	f-to-c	in	the	heptad	repeat	units	of	FosW	(Figure	2,	compounds	
1-5	and	Figure	S1).		Compounds	1	and	3	had	similar	helicity	(44	%	and	40	%)	to	FosW	(41	%),	
while	 compounds	 2,	 4	 and	 5	 were	 more	 alpha-helical	 (62	 %,	 59	 %,	 79	 %	 respectively).	
However,	only	compounds	1	and	2	showed	higher	binding	affinity	for	Jun	(Kd	9.6	nM,	16.2	
nM)	relative	to	FosW	(Kd	39	nM),	whereas	4	and	5	had	binding	comparable	to	FosW	(Kd	40	
nM	and	29	nM).	Compound	3	did	not	display	any	affinity	for	Jun	indicating	that	crosslinking	
at	those	positions	was	unproductive.	
	Since	1	had	the	highest	binding	affinity,	a	 lactam	bridge	crosslinking	residues	K29-
D33	 was	 retained	 in	 compounds	 6-9	 (Figure	 2),	 which	 also	 contained	 a	 second	 bridge	
between	 residues	4-8,	8-12,	15-19	or	23-26	 to	 further	 increase	helicity	 (53	%,	85	%,	78	%	
and	82	%)	over	the	moderately	helical	compound	1	(44	%).	Compounds	7,	8,	and	9	retained	
affinity	 for	 Jun	 (Kd	8.6	nM,	9.9	nM	and	11	nM)	while	6	had	 slightly	 less	affinity.	 Since	7-9	
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retained	 affinity	 (Kd	 <10	nM)	 and	had	high	helicity	 (>70	%),	 the	 constraints	 used	 in	 these	
compounds	became	the	focus	of	our	efforts	to	downsize	FosW.	
Neither	22-residue	peptides	10	and	11,	with	lactam	bridges	at	positions	15-19,	22-26	
and	29-33,	nor	the	same	length	peptides	12	and	13	with	lactam	crosslinks	from	positions	8-
12,	 15-19	 and	 22-26	 (12-13),	 were	 able	 to	 bind	 to	 Jun	 (trance	 did	 not	 exceed	 the	 non-
interaction	 average	 or	 displayed	 low	 Tm	 values),	 and	 only	 10	 had	 helicity	 above	 40	 %.	
Extending	the	N-terminus	to	25	residues,	while	incorporating	a	lactam	crosslink	at	positions	
22-26	 gave	 14-15,	 with	 Kd	 2.2	 μM	 and	 1	 μM	 respectively.	 Removing	 the	 22-26	 bridge	
resulted	in	loss	of	binding	affinity.	Compound	15	was	highly	alpha	helical	(65	%).	Shortening	
the	peptide	to	22	residues	(17)	abolished	affinity	for	Jun.	
In	 an	 effort	 to	 restore	 binding	 affinity,	 the	 sequence	 length	 was	 extended	 to	 29	
residues.	Compounds	were	 truncated	 from	the	N-terminus	and	 lactam	bridges	 inserted	at	
positions	 7-11	 and	29-33	 (18),	 or	 11-15	 and	29-33	 (19).	 These	 compounds	had	 significant	
binding	 affinity	 (Kd	 =	 56	 nM	 and	 100	 nM)	 and	 helicity	 (72	 %	 and	 64	 %).	 Subsequent	
truncation	from	the	N-terminus	of	19	to	25	residues	gave	compound	20	with	higher	affinity	
(Kd	2	μM)	and	alpha	helicity	(85	%)	(Figure	S1).	
Having	 identified	 some	 shorter	 peptides,	 isothermal	 titration	 calorimetry	 (ITC)	
(Figure	3	and	Figure	S2)	was	used	to	assess	enthalpic	and	entropic	energy	contributions	to	
binding	to	Jun	(Table	1).	Compounds	14	and	15	had	the	highest	negative	entropy	of	binding	
(TΔS	=	 -5.7	 and	 -5.2	 kcal	 per	mol),	while	 peptides	18-20	 had	 improved	ΔG	 retention.	 The	
25mer	peptide	20	retained	substantial	binding	free	energy	through	entropic	gain	and	was	a	
good	compromise	between	shortening	 the	sequence	 (reducing	enthalpy)	and	constraining	
the	helix	(increasing	entropy).	
Helicity	is	expected	to	be	an	important	contributor	to	binding	affinity	2,	5.	Interacting	
peptides	had	homomeric	helicities	≥	39	%	with	a	mean	helicity	 (63	%)	substantially	higher	
than	for	FosW	(41	%),	whilst	non-interacting	peptides	had	a	mean	helicity	of	37	%,	close	to	
that	of	FosW.	When	mixed	with	Jun,	interacting	peptides	had	heteromeric	helicities	≥44	%	
with	 a	 mean	 helicity	 (55	 %),	 much	 higher	 than	 FosW–Jun	 (37	 %),	 whilst	 non-interacting	
peptides	 had	 a	mean	 helicity	 of	 26	%.	However,	 contrary	 to	 expectations,	 there	were	 no	
	 8	
strong	 relationships	 between	 helicity,	 affinity	 and	 entropy	 beyond	 these	 qualitative	
thresholds	(See	Supplementary	Information).	
	
Peptide	20	binds	Jun	effectively	via	entropic	pre-organisation		
Peptide	20	consists	of	a	NΔ9CΔ3	peptide	(loss	of	9	residues	from	the	N-terminus	and	
3	from	the	C-terminus	relative	to	FosW;	Figure	2)	and	can	make	8	a/d	and	2	e/g	favourable	
interactions	with	 Jun,	 compared	with	 10	a/d	 and	 3	e/g	 favourable	 interactions	 for	 FosW	
binding	 to	 Jun.	 It	 also	produced	coiled	 coils	with	 Jun	 that	were	much	more	helical	 (62	%)	
than	FosW–Jun	(37	%)	(Figure	3).	The	 increased	helicity	can	be	attributed	to	the	two	helix	
constraints	positioned	at	the	N-	and	C-terminus.	Therefore	despite	truncation	of	one-third	
of	the	sequence	relative	to	FosW,	significant	binding	energy	was	maintained.	Furthermore,	
20	 displayed	 the	 expected	 entropy	 benefit	 conferred	 by	 the	 two	 helix	 constraints,	 a	
significant	 gain	 of	 +3.2	 ±	 0.5	 kcal/mol	 to	 TΔS	 compared	 to	 FosW–Jun	 (Figure	 3),	 thereby	
compensating	 for	 a	 loss	 of	 enthalpy	 accompanying	 the	 sequence	 shortening	 from	 FosW.	
Peptide	20	 demonstrated	 that	 the	N-terminus	 of	 FosW	 is	 not	 absolutely	 required	 for	 Jun	
interaction,	 and	 that	 N-terminal	 truncation	 is	 possible	 with	 correct	 placement	 of	 helix-
inducing	 constraints.	 The	 success	of	 peptide	20	 is	 striking	when	 comparing	 the	helicity	of	
20–Jun	 (62	 %)	 with	 the	 unconstrained	 counterpart,	 LIN20–Jun	 (38	 %).	 The	 latter	 is	
comparable	 to	 that	 of	 FosW–Jun	 (37	 %)	 but,	 in	 contrast,	 displayed	 insignificant	
heterodimerisation	 compared	 to	 either	 dimer	 as	 measured	 by	 thermal	 denaturation	
experiments	(Figure	3).	As	a	result,	the	binding	of	20	to	Jun	(Kd	2.0	±	0.0	μM)	is	almost	30-
fold	greater	than	for	LIN20	(Kd	≈	55	μM)	(Figure	3).	
	
Development	of	cell	permeable	compounds	
Compounds	18	 (29	 residues)	 and	20	 (25	 residues)	were	 identified	as	 compromises	
between	 truncating	 the	peptide	 sequence	and	 retaining	 some	of	 the	affinity	observed	 for	
FosW	(37	residues)	binding	to	Jun.	To	investigate	whether	these	peptides	would	enter	cells,	
fluorescein	 isothiocyanate	 (FITC)	 was	 coupled	 to	 their	 N-terminus	 via	 a	 flexible	 linker	 (6-
aminohexanoic	acid)	to	allow	detection	via	flow	cytometry	and	live	cell	confocal	microscopy.	
There	was	negligible	uptake	of	either	FITC-18	or	FITC-20	into	MCF-7	breast	cancer	cells	after	
	 9	
1	h	or	6	h	(Figure	4B).	Thus,	further	modification	of	these	peptides	to	promote	cell	uptake	or	
penetration	was	needed	if	these	compounds	were	to	exhibit	biological	activity	in	cells.	Three	
strategies	 were	 investigated	 for	 delivering	 these	 helix-constrained	 peptides	 into	 cells:	
attaching	 a	 lipid,	 appending	 a	 cell	 penetrating	 peptide	 (CPP)	 sequence,	 or	 replacing	 the	
polar	 helix-constraining	 lactam	 bridges	 with	 more	 hydrophobic	 helix-constraining	
hydrocarbon	linkers.		
Firstly,	palmitic	acid	was	conjugated	to	the	N-terminus	of	peptide	20	to	give	Pal-20,	
anticipated	to	interact	with	the	lipid	bilayer	to	enhance	uptake	31.	However,	the	conjugate	
showed	no	significant	binding	to	 Jun,	as	measured	by	CD	or	 ITC	techniques.	Secondly,	 the	
first	 ten	 residues	of	 cationic	 cell	 penetrating	peptide	 sequence	 TAT	 derived	 from	HIV-1	 32	
was	attached	to	the	C-terminus	of	20	to	give	20-TAT48-57,	but	this	is	only	known	to	enhance	
peptide	uptake	into	the	cytoplasm,	not	the	nucleus.	An	additional	nuclear	localisation	signal	
sequence	from	the	SV40	large	T-cell	antigen	33	was	therefore	also	appended	to	produce	20-
NLS-TAT48-57,	for	the	purpose	of	both	enhancing	cell	uptake	and	directing	20	to	the	nucleus.	
These	peptide	appendages	did	not	significantly	affect	binding	affinity	for	Jun,	and	a	positive	
TΔS	term	was	maintained	(Table	1).	The	third	strategy	involved	replacing	the	lactam	bridges	
in	compounds	18	and	20	with	more	hydrophobic	hydrocarbon	bridges	to	give	18-HC	and	20-
HC,	which	was	found	to	reduce	binding	affinity	for	Jun	(Kd	320	nM	and	15	µM,	respectively)	
but	maintain	a	positive	TΔS	term	(Table	1).	
Cell	uptake	was	monitored	by	flow	cytometry	using	FITC	labelled	analogues	of	18HC,	
20HC,	20-TAT48-57	 and	20-NLS-TAT48-57	 (Figure	 4B).	20-NLS-TAT48-57	 showed	 the	 highest	 cell	
uptake	with	the	most	fluorescence	at	1h	and	6	h,	comparable	to	FITC-labelled	TAT48-57	alone.		
Cells	incubated	with	20-TAT48-57	displayed	increased	levels	of	fluorescence	at	6h,	whilst	18HC	
and	20HC	had	comparable	levels	of	cell	uptake	after	6	h.	We	next	analysed	these	peptides	
by	 live	 cell	 confocal	 microscopy	 to	 observe	 how	 these	 compounds	 were	 distributed	
throughout	the	cell.	FITC-18HC	and	FITC-20HC	localised	differently	within	MCF-7	cells.	FITC-
18HC	was	 freely	 distributed	 throughout	 the	 cytosol	 and	 the	 nucleus,	 whereas	 FITC-20HC	
was	mainly	 trapped	within	 endosomes	 or	 aggregated	within	 the	 cell	 (Figure	 4B),	 possibly	
owing	 to	 a	 change	 in	 the	 net	 charge	 of	 the	 protein	 (-4	 vs	 -2).	 TAT48-57	 (FITC-20-TAT48-57)	
showed	cytosolic	uptake	and	a	small	amount	of	nuclear	 localisation.	However,	addition	of	
the	nuclear	localisation	signal	(FITC-20-NLS-TAT48-57)	promoted	very	efficient	cellular	uptake	
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and	 led	 to	 much	 greater	 nuclear	 localisation.	 All	 four	 compounds	 were	 distributed	
differently	in	the	cells,	potentially	impacting	on	their	biological	properties.	
	
Antiproliferative	activity	in	human	breast	cancer	cells	
Both	 MCF-7	 and	 ZR75-1	 are	 breast	 cancer	 cell	 lines	 that	 are	 dependent	 on	 AP-1	
activity	 for	 proliferation	 34-35.	Having	demonstrated	 that	C-terminal	 appendage	of	 cationic	
cell	 penetrating	 peptides	 was	 sufficient	 to	 facilitate	 efficient	 cellular	 uptake	 and	 nuclear	
localisation	of	20,	or	alternatively	that	hydrocarbon	staples	were	sufficient	to	facilitate	cell	
uptake	and	nuclear	localisation	of	18,	we	next	sought	to	investigate	whether	these	peptides	
inhibited	cell	proliferation.	Treatment	with	20,	20HC,	18	or	18HC	did	not	affect	proliferation	
of	MCF-7	or	ZR75-1	cells	at	the	concentrations	tested	(Figure	4C,	4D).	However,	20-TAT48-57	
did	significantly	reduce	proliferation	of	both	MCF-7	(83	%	reduction)	and	ZR75-1	cells	(70	%	
reduction)	at	30	μM,	while	20-NLS-TAT48-57	at	the	same	concentration	reduced	proliferation	
to	an	even	greater	extent	(95	%	and	96	%	respectively,	Figure	4D).	Neither	TAT48-57	nor	NLS-
TAT48-57	 alone	 at	 the	 same	 concentration	 reduced	 cell	 viability	 (Figure	 4C,	 4D),	 and	 no	
peptide	 showed	 any	 haemolytic	 activity	 on	 red	 blood	 cells	 after	 six	 hours	 at	 peptide	
concentrations	up	to	30	μM,	indicating	that	cell	viability	was	not	inhibited	by	the	peptides	
through	non-specific	membrane	disruption	(Table	S2).		
These	 results	 indicate	 that	 our	 successful	 strategy	 of	 downsizing	 Fos	 to	 helix-
constrained	short	peptides	has	overcome	the	energy	barrier	to	binding	Jun.	The	next	hurdle	
was	 to	modify	 the	 short	 peptide	 antagonists	 for	 cell	 uptake	 and	 nuclear	 localisation.	 Cell	
uptake	 was	 achieved	 by	 making	 the	 helix	 constraints	 more	 hydrophobic,	 but	 a	 nuclear	
localisation	 signal	was	 still	 required	 to	 access	 the	 intracellular	 target	 of	 Fos	 peptides	 and	
affect	proliferation	of	AP-1	containing	breast	cancer	cells.	These	important	steps	taken	here	
to	target	the	Fos-Jun	binding	interface	provide	a	valuable	platform	for	further	development	
of	Fos-derived	small	molecules	as	AP-1	inhibitors	in	cancer	therapy.		
	
DISCUSSION	
Helix	constraints	confer	affinity	to	cFos	peptides	enabling	their	shortening		
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	 The	 37-residue	 truncated	 analogue	 of	 cFos	 (FosW)	 has	 been	 crystallised	 here	 in	
complex	with	a	Jun	peptide.	FosW	is	an	antagonist	of	the	interaction	of	Jun	with	Fos	26.	The	
crystal	structure	of	FosW-Jun	has	identified	the	relative	positioning	of	amino	acid	sidechains	
in	FosW	and	Jun	and	their	specific	 involvement	in	 inter-helix	 interactions	that	stabilise	the	
heterodimer	in	a	coiled-coil	complex	(Figure	1).	The	structure	provides	valuable	information	
as	 to	 the	 optimal	 sites	 for	 modifying	 Fos	 without	 disrupting	 interhelical	 interactions.	
Nevertheless,	 truncating	 this	peptide	was	 found	 to	 substantially	attenuate	binding	affinity	
for	 Jun,	 due	 principally	 to	 loss	 of	 binding	 enthalpy,	 as	 demonstrated	 by	 the	 linear	
counterpart	of	20	(LIN20)	(Table	1).	To	compensate	for	this	loss	of	enthalpy	upon	truncating	
the	 FosW	 sequence,	 we	 have	 investigated	 the	 effect	 of	 incorporating	 one,	 two	 or	 three	
helix-inducing	(i→i+4)	lactam	bridges	at	positions	in	FosW	away	from	the	helix-helix	binding	
interface	 with	 Jun.	 These	 constraints	 were	 anticipated	 to	 reduce	 the	 conformational	
entropic	 penalty	 for	 helix	 formation	 36.	 Promotion	 of	 helicity	 was	 anticipated	 to	 improve	
binding	affinity	for	Jun,	which	is	dependent	on	a	supercoiling	event	between	helical	partners	
2,	 37-38.	 By	 increasing	 helicity	 in	 truncated	 FosW	 analogues,	 we	 anticipated	 reducing	 the	
entropic	 penalty	 associated	 with	 pre-organising	 the	 shortened	 helix	 for	 target	 binding,	 a	
strategy	 used	 successfully	 to	 enable	 downsizing	 of	 other	 α-helical	 partners	 in	 protein-
protein	interactions	5-6,	39.	
Lactam	 helix-inducing	 constraints	 at	 (i→i+4)	 positions	 were	 chosen	 due	 to	 their	
ability	 to	 impart	 greater	 alpha	 helicity	 per	 residue	 relative	 to	 other	 linkers,	 such	 as	
hydrocarbons,	triazoles,	m-xylene	thioether	and	alkyl	thioether	9,	and	due	to	the	simplicity	
and	 minimal	 sequence	 disturbance	 of	 merely	 connecting	 amino	 acid	 sidechains	 to	 form	
lactams.	 Positioning	 these	 cyclic	 pentapeptide	motifs	 within	 the	 FosW	 sequence	 induced	
substantial	 α-helicity	 (60-77	 %)	 relative	 to	 the	 linear	 sequence,	 despite	 significant	
shortening.	However,	we	 find	here	 that	high	helicity	alone	 in	 Fos	peptide	analogues	does	
not	 guarantee	 high	 affinity	 for	 Jun	 (See	 Supplementary	 Information),	 reinforcing	 the	
importance	of	 sequence	 in	coiled	coil	 formation	and	stability.	The	use	of	helix	 constraints	
was	anticipated	 to	permit	at	 least	 some	 truncation	of	 the	FosW	sequence	without	 loss	of	
Jun	binding.	Indeed,	truncation	from	either	terminus	coupled	with	careful	positioning	of	the	
helix-inducing	constraints	between	non-interfacial	b,	c	and	f	residues,	particularly	at	peptide	
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termini,	has	successfully	enabled	 identification	of	 truncated	peptides	which	maintain	both	
high	helicity	and	affinity	for	Jun	(Figure	2,	3).	
Compounds	18	(29	residues,	Kd	56	nM)	and	20	(25	residues,	Kd	2	µM)	were	identified	
as	 compromises	between	 shortening	 the	peptide	 sequence	 (22	%	and	33	%,	 respectively)	
relative	to	FosW	and	retaining	some	of	the	affinity	observed	for	FosW	(37	residues)	binding	
to	 Jun.	 Additionally,	18	and	20	 retained	high	 helicity	 (69	%	 and	 62	%,	 respectively)	when	
bound	 to	 Jun	 (15	 %	 helical	 in	 isolation27),	 compared	 with	 72%	 and	 85%	 in	 isolation	 (i.e.	
homodimeric	–	see	Figure	S2).	For	20	there	was	a	clear	entropic	gain	that	contributed	to	the	
favourable	 interaction	 free	 energy,	 and	 this	 partially	 compensated	 for	 a	 loss	 in	 binding	
enthalpy.	Conversely,	LIN20	suffered	the	same	enthalpic	loss	as	20	(within	1.1	kcal/mol),	but	
without	constraints	there	was	no	entropy	gain,	and	so	ΔG	was	reduced	by	43	%	compared	to	
FosW.	 The	 helix-inducing	 constraints	 in	 20	 therefore	 provide	 19	 %	 of	 the	 free	 energy	 of	
binding	 compared	 to	 the	 unconstrained	 peptide,	 translating	 to	 a	 27-fold	 improvement	 in	
affinity	 for	 Jun.	 This	 finding	 demonstrates	 the	 value	 of	 helix-inducing	 constraints	 in	
truncated	peptides	for	maintaining	significant	bioactivity.	These	two	peptides	show	greater	
ligand	 efficiency	 (ΔG	 per	 unit	 molecular	 weight),	 higher	 entropy	 gain,	 and	 greater	 water	
solubility	 than	 similar	 length	 analogues,	 14	 and	 15.	 Peptides	 20	 and	 18	 were	 therefore	
chosen	for	the	next	stage,	the	testing	of	cellular	uptake	and	functional	activity.		
	
Helicity,	entropic	stabilisation	and	binding	affinity	
Helix-inducing	 constraints	 are	 expected	 to	 confer	 an	 entropy	 advantage	 by	 pre-
organising	 peptides	 in	 the	 helix-binding	 conformation	 preferred	 by	 the	 target.	Molecules	
with	 greater	 helicity	might	 better	 form	 coiled-coils	 5,	 37-38,	 however	we	 find	 this	 to	 be	 an	
over-simplification.	For	the	case	of	a	coiled	coil,	there	is	likely	a	limit	to	the	entropy	value	of	
pre-organising	 a	 helical	 structure.	 Above	 a	 certain	 threshold	 helicity,	 conformational	
entropy	may	 oppose	 coiled-coil	 formation	 27,	 perhaps	 reflecting	 a	 need	 for	 flexibility	 in	 a	
helix	to	enable	some	distortion	necessary	for	supercoiling	40-41.	A	key	issue	with	a	coiled-coil	
is	 that	 there	 is	 usually	 a	 fairly	 even	 contribution	 of	 residues	 along	 the	 entire	 coil	 to	 the	
binding	energy,	with	 fewer	hot	spots	 localised	 in	a	single	 region	of	 the	sequence	that	can	
form	the	basis	for	truncation.	It	is	notable	that	truncation	to	20	results	in	substantial	loss	of	
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enthalpy,	 consistent	with	 enthalpy	 contributions	 from	 residues	 all	 along	 the	 coiled	 coil	 5.	
This	 may	 prevent	 further	 antagonist	 truncation,	 requiring	 innovation	 to	 increase	 both	
entropy	 and	 enthalpy	 through	 unnatural	 amino	 acid	 replacements	 that	 still	 enable	 coiled	
coil	formation.	Consequently,	very	few	short	helical	antagonists	of	coiled	coil	PPIs	have	been	
described	in	the	literature	to	date	25.	
	
Cell	uptake	and	nuclear	localisation	
AP-1	is	localised	in	the	cell	nucleus,	so	the	development	of	Fos-derived	peptides	that	
can	antagonise	Fos-Jun	binding	is	only	the	first	step	towards	drugs	that	can	modulate	AP-1	
in	vivo.	The	unconstrained	and	polar	FosW	peptide	antagonist	of	 Jun–Fos	binding	has	 low	
conformational	 stability,	 high	 susceptibility	 to	 degradation	 by	 proteases	 in	 blood	 and	 in	
cells,	 and	poor	permeability	 across	 cell	membranes.	Helix	 constraints	have	been	 found	 to	
improve	all	of	these	properties	for	some	peptides	5-6.	However,	cellular	uptake	is	difficult	to	
predict.	It	is	highly	dependent	on	the	peptide	sequence,	the	type	of	helix	constraint,	and	the	
cell	type	42.		
Given	the	size	of	our	short	FosW-derived	peptides	compared	to	cellular	Jun	and	Fos	
proteins,	it	was	our	aim	to	assess	their	ability	to	compete	with	these	for	an	interaction	with	
Jun	 inside	the	cell.	We	chose	20	 for	assessment	of	cellular	uptake	and	nuclear	 localisation	
because	of	its	higher	affinity	(Kd	2	μM)	compared	to	the	shortest	Jun-derived	antagonist	of	
Jun-Fos	 interactions	 (Kd	 7.3	μM)	 reported	previously	 5,	 and	 the	 greater	 expected	 value	of	
Fos-peptides	as	antagonists	against	oncogenic	Jun	11-12,	30	than	for	Jun-peptides	against	cFos	
5.	While	lactam-bridges	were	very	effective	as	helix-inducing	constraints	in	FosW-derivative	
peptides,	 there	was	no	evidence	 for	 cell	 internalisation	of	20.	 Previous	 reports	of	 the	cell	
penetrating	potential	of	hydrocarbon	constrained	peptides	 42	encouraged	 the	synthesis	of	
the	analogue	FITC-20HC.	While	that	peptide	did	pentrate	cells,	it	did	not	display	favourable	
intracellular	distribution	for	AP-1	targeting.	The	 longer	peptide	analogue	18HC,	which	also	
had	higher	affinity	 for	 Jun	 than	20HC,	was	also	generated	 to	compare	cellular	uptake	and	
activity.	 Cell	 uptake	 did	 increase,	 but	 there	 was	 little	 uptake	 into	 the	 nucleus	 and	
consequently	the	peptide	concentration	may	not	have	been	high	enough	for	AP-1	inhibition.	
We	 therefore	added	TAT48-57	 or	 a	NLS-TAT48-57	 appendage	 to	help	drive	higher	 cell	 uptake	
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and	 target	more	20	 to	 the	 cell	 nucleus	where	AP-1	 is	 active	 (Figure	 4).	 TAT48-57	 increased	
uptake	and	favourable	distribution,	which	further	increased	with	additional	inclusion	of	the	
NLS	 sequence	 (Figure	 4).	 Considering	 the	 minimal	 concentrations	 (µM)	 known	 to	 be	
required	 for	 internalisation	 of	 cationic	 CPP	 conjugates	 43,	 these	 conjugates	 of	 20	 were	
considered	to	have	been	delivered	at	a	minimum	effective	concentration.	Cytoplasmic	co-
translational/post-translational	 sequestration	of	 Jun	before	nuclear	 transport	may	 also	be	
desirable	 to	 expedite	 Jun	 degradation	 by	 cytoplasmic	 ubiquitin/proteasomal	 pathways.	
Thus,	 the	 improved	nuclear	and	cytosolic	presence	of	20-NLS-TAT48-57	over	20-TAT48-57	was	
considered	to	be	promising	for	AP-1	inhibition.	
	
Antiproliferative	activity	of	18	and	20	in	breast	cancer	cells		
AP-1	is	known	to	be	overexpressed	in	many	breast	cancers	44,	where	it	drives	tumour	
initiation	 and	development	 45,	 and	 thus	 is	 an	 important	 target	 for	 cancer	 therapy.	MCF-7	
and	ZR75-1	breast	cancer	cells	are	dependent	on	AP-1	for	expression	of	a	variety	of	genes	in	
response	 to	 pro-oncogenic	 growth	 factors	 34,	 including	 extracellular	 matrix	
metalloproteinase	MMP9	46-47	and	G1→S	phase	regulator	Cyclin	D1	24,	35,	such	that	reduced	
metastatic	 potential	 and	 cancer	 cell	 proliferation	 results	 from	 repression	 of	 these	 genes.	
Poor	uptake,	endosomal	trapping	and/or	aggregation,	and	low	Jun	binding	affinity	may	have	
prevented	 20HC	 from	 affecting	 cell	 viability,	 whilst	 poorly	 internalised	 18HC	 also	 did	 not	
reduce	cancer	cell	viability	despite	apparently	avoiding	endosomal	trapping	or	aggregation	
(Figure4B).	However,	conjugation	of	both	TAT48-57	and	the	SV40	NLS	to	20	led	to	significant	
reduction	 in	 the	viability	of	both	MCF-7	and	ZR75-1	breast	cancer	cells.	This	suggests	 that	
cell	and	nuclear	penetration	were	the	limiting	factors	for	AP-1	inhibition	by	20	since	TAT48-57	
and	 NLS	 appendages	 alone	 had	 no	 effect	 on	 cell	 viability	 and	 non-specific	 cell	 lysis	 was	
negligible.	 Thus,	 we	 have	 demonstrated	 that	 once	 sufficiently	 internalised	 into	 the	 cell	
nucleus,	 20	 displays	 significant	 inhibition	 of	 AP-1-driven	 oncogenesis.	 Moreover,	 once	
internalised	 the	 CPP	 component	 of	 the	 peptide	 is	 predicted	 to	 expendable,	 without	
significant	effect	on	the	activity	of	20.		
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CONCLUSION	
The	 strategy	 of	 iterative	 sequence	 truncation,	 coupled	 with	 insertion	 of	 helix-
inducing	constraints	at	appropriate	positions,	was	used	to	reduce	the	size	of	Fos	to	peptide	
fragments	 as	 antagonists	of	 Fos-Jun	 coiled	 coil	 formation.	 The	 first	 crystal	 structure	of	 an	
AP-1	 antagonist,	 a	 Fos-derived	 peptide	 complexed	 with	 Jun,	 was	 used	 to	 design	 helix-
constrained	and	truncated	peptides	that	similarly	bound	to	Jun.	Several	rounds	of	iteration	
led	to	peptides	18	and	20,	which	were	efficient	Jun-binding	ligands	relative	to	their	size	and	
were	 able	 to	 inhibit	 the	 Fos–Jun	 interaction.	 Compounds	 18	 and	 20	 represented	
compromises	between	downsizing	to	a	minimal	binding	sequence	and	retaining	appreciable	
binding	 affinity	 for	 Jun.	 Isothermal	 titration	 calorimetry	measurements	 revealed	 that	 the	
helix-inducing	 constraint	 provided	 an	 entropic	 advantage	 for	 binding	 to	 Jun	 relative	 to	
analogous	 unstructured	 short	 peptides.	 Importantly,	 the	 cell	 penetrating	 peptide	 TAT48-57	
together	with	 the	nuclear	 localisation	 signal	 peptide	 SV40,	 or	 alternatively	 a	 hydrocarbon	
(i→i+4)	helix-constraining	 linker,	enabled	substantial	cell	uptake	and	delivery	of	18	and	20	
into	 the	nucleus	of	 cells	where	AP-1	 is	 active.	With	 these	adaptations,	 compound	20	was	
able	to	both	enter	the	nucleus	of	cancer	cells	and	reduce	their	proliferation	 in	vitro	at	low	
µM	concentrations.	This	potency	compares	favourably	with	small	molecule	AP-1	 inhibitors	
such	as	momordin	I	(IC50	≈	30	μM)	and	T-5524	(IC50	≈	10	μM)	that	have	reached	clinical	trials	
18,	48.	Compound	20	represents	one	of	few	examples	to	date	of	a	helix-constrained	peptide	
that	can	modulate	a	PPI	featuring	coiled-coil	peptides	25,	42.	The	approach	highlighted	here,	
using	 helix-inducing	 constraints	 to	 compensate	 for	 shortening	 the	 sequence	 of	 a	 binding	
partner	 in	 a	 coiled	 coil	 transcription	 factor,	 shows	 considerable	 promise.	 Further	
development	of	Jun	antagonists	based	on	truncating	Fos	is	required	to	generate	useful	AP-1	
inhibitors	suitable	for	treating	cancers	featuring	AP-1	dysregulation.	
	
METHODS				
Circular	Dichroism	(CD	spectra	and	thermal	melts)	
Coiled	 coil	 stability	 was	 analysed	 as	 previously	 described	 5	 using	 a	 Chirascan	 (Applied	
Photophysics)	 instrument,	 recording	 ellipticity	 of	 homotypic	 (peptide)	 or	 heterotypic	 (1:1	
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peptide:Jun	 stoichiometric	mix)	 samples	 at	 a	 total	 peptide	 concentration	 (Pt)	 of	 150	 μM,	
dissolved	in	10	mM	potassium	phosphate	buffer	with	100	mM	potassium	fluoride,	pH	7.		
Isothermal	titration	calorimetry	(ITC)	
Coiled	 coil	 interaction	 thermodynamics	 were	 assessed	 as	 previously	 described	 5	 using	 a	
Microcal	VP-ITC	instrument	(GE	Healthcare).	Jun	at	100	μM	-	3	mM	was	injected	into	peptide	
homotypic	samples	at	9	μM	–	200	μM	in	circular	dichroism	buffer.		
	
	
SUPPORTING	INFORMATION	
Peptide	 characterisation,	 Peptide	 synthesis	 and	 purification,	CD	measurements	 and	 fitting	
procedures,	 ITC	 measurements	 and	 fitting	 procedures,	 X-ray	 crystallography	 procedures	
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FIGURE	LEGENDS	
Figure	1:	Crystal	structure	of	the	FosW–Jun	coiled	coil.	Top	left:	FosW	and	Jun	sequences.	
Stabilising	interhelical	hydrophobic	interactions	(ai-a’i	and	di-d’i)	are	shown	as	vertical	lines	
and	 specificity-conferring	 interhelical	 electrostatic	 interactions	 (gi-e’i+7	 and	 ei-g’i-7),	 are	
shown	 as	 green	 arrows.	 Heptad	 register	 is	 shown	 in	 italics	 above	 FosW	 sequence.	 Left:	
Helical	 wheel	 diagram	 of	 FosW	 (showing	 residues	 selected	 from	 Fos	 library	 in	 red)	 in	
interaction	 with	 Jun,	 including	 interhelical	 interactions	 between	 e	 and	 g	 residues	 (green	
arrows).	Adapted	from	source	26.	Right:	Crystal	structure	of	the	FosW–cJun	coiled	coil	at	2.3	
Å	resolution.	FosW	is	shown	as	a	red	helix,	with	cJun	shown	as	a	green	helix.	Side	chains	for	
a,	d,	e	 and	g	 residues	 only	 are	 shown,	 using	 CPK	 colouring.	 Helices	 run	 from	N-terminus	
(top)	 to	 C-terminus	 (bottom).	 See	 Table	 S1	 for	 crystallisation	 and	 structure	 solving	
parameters.	 Model	 rendered	 with	 the	 PyMOL	 Molecular	 Graphics	 System,	 Version	 1.8	
Schrödinger,	LLC.	
Figure	2:	Helix-constrained	and	truncated	Fos	peptides.	Design	template	FosW	sequence	in	
bold.	Heptad	register	a-g	through	each	heptad	of	FosW	in	italics.	Helix	constraints	between	
lysine	and	aspartate	are	shown	in	blue.	Standard	single	letter	amino	acid	code	except	Pal	=	
palmitic	acid,	TAT48-57	=	First	10	residues	of	the	HIV-1	Tat	peptide	32,	NLS	=	the	monopartite	
SV40	large	T-antigen	nuclear	localisation	signal	33,	Ac-	=	N-terminal	acetyl	modification,	-NH2	
=	C-terminal	amine,	X	=	 (S)α-(2’-pentenyl)alanine.	Dissociation	constants	 (Kd)	measured	by	
isothermal	 titration	 calorimetry	 (ITC),	 and	 fractional	 helicites	 calculated	 from	 ellipticity	
measured	 by	 circular	 dichroism	 spectroscopy	 (CD)	 using	 Equation	 4	 (see	 Supporting	
Information)	 49.	 Constraint	 of	 all	 heptads	 except	 Heptad	 3	 generated	 full	 length	 peptides	
(minus	AS	and	GAP	capping	motifs)	with	similar	dissociation	constants	to	that	of	FosW	but	
improved	helicity,	whist	addition	of	a	second	constraint	was	generally	effective	in	inducing	
further	increased	helicity,	and	even	lower	dissociation	constants.	Truncations	from	N-	and	C-
termini	were	effective	if	combined	with	optimal	positioning	of	constraints.	ITC	experiments	
not	 performed	 because	 binding	 measured	 by	 CD	 was	 negligible	 are	 labelled	 “ND”	 (“not	
determined”).	 ITC	 experiments	 that	 generated	 binding	 too	 weak	 for	 accurate	 fitting	 are	
labelled	“NF”	(“not	fit”).	
Figure	3:	Peptide	20	binds	Jun	and	tolerates	cell	penetrating	peptide	appendages.	Thermal	
denaturation	 profiles	 (A,	 C)	 and	 isothermal	 titration	 calorimetry	 (B,	 D)	 of	 peptide:Jun	
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mixtures	compared	to	FosW–Jun.	 (A,	C)	Thermal	melt	data	 is	 reported	as	change	 in	mean	
residue	ellipticity	(MRE;	units	deg	cm2/dmol),	as	a	function	of	circular	dichroism	ellipticity	at	
222	 nm	with	 temperature.	 Blue:	 peptide	 alone,	 red:	 equimolar	 mix	 of	 peptide	 with	 Jun,	
grey:	average	of	Jun	and	peptide	alone	(representing	non-interaction),	black:	Jun	alone.	(B,	
D)	Raw	isotherms	(top	panels)	and	fitted	data	(bottom	panels)	(both	baseline	corrected)	for	
peptides	with	Jun	compared	to	FosW.	Injection	enthalpies	for	the	buffer	into	buffer	control	
(blue	text	label)	on	the	NLS-TAT48-57	plot	are	translated	by	-0.05	μcal/sec	for	clarity	relative	
to	those	for	Jun	into	NLS-TAT48-57.	In	shortened	peptide	20,	constraints	induce	high	helicity	
despite	truncation,	and	this	peptide	retains	significant	binding	free	energy	of	FosW	despite	
loss	 of	 interaction	 contacts	 due	 to	 entropic	 stabilisation.	 In	 contrast,	 linear	 counterpart	
LIN20	displays	poor	helicity	and	27-fold	reduced	affinity	for	Jun	compared	to	20.	
Figure	 4:	 Intracellular	 delivery	 of	 18	 and	 20	 alone	 versus	 with	 appended	 cationic	 cell	
penetrating	peptides.	(A)	Peptides	were	incubated	at	10	μM	for	one	or	six	hours	at	37	°C	in	
serum	 free	 media	 on	 MCF-7	 cells.	 Quantitation	 by	 flow	 cytometry	 with	 fluorescence	
intensity	 calculated	 from	 live	 single	 cells.	 Data	 shown	 are	 means	 (+	 SEM)	 of	 four	
independent	 repeats	 (B)	 Live	 cell	 confocal	 microscopy	 of	 MCF-7	 cells.	 Peptides	 were	
incubated	at	10	μM	for	6	h	at	37	°C	in	serum	free	media.	Nuclei	were	counterstained	with	
Hoechst.	Scale	bar	=	20	μm.	Viability	of	MCF-7	(C)	and	ZR75-1	(D)	breast	cancer	cells	after	a	
96-hour	incubation	with	the	indicated	peptide	concentrations	in	complete	medium.	Data	is	
normalised	to	vehicle	(DMSO)	control.	Data	shown	are	means	(+	SEM)	of	three	independent	
experiments.	 *	 P	 <	 0.05,	 ****	 P	 <0.0001	 (Student's	 T-test)	 decrease	 relative	 to	 DMSO	
control.	
Table	 1:	 Thermodynamic	 parameters	 for	 Jun	 interaction	 with	 lactam	 constrained	 FosW	
derivative	 peptides.	 Data	 from	 CD	 and	 ITC	measurements	 (2	 s.f.).	 θ	 is	 raw	 CD	 ellipticity	
(mdeg).	Equations	for	fractional	helicity	and	the	Gibbs-Helmholtz	equation,	from	which	TΔS	
is	 calculated	 as	 ΔH	 –	 ΔG,	 are	 provided	 in	 the	 Supplementary	 Information.	 FosW–Jun	 CD	
values	 from	 Worrall	 and	 Mason	 (2011).	 CD	 values	 are	 taken	 from	 representative	 single	
measurements,	 which	 are	 typically	 reproducible	 in	 biological	 replicates	 to	 ±	 1	 °C	 for	 Tm,	
within	5	%	for	fractional	helicity	and	222:208	ratio	(θ222/208),	and	within	10	%	for	Kd	and	∆G	
(data	not	shown).	ITC	values	are	the	arithmetic	mean	of	at	least	two	independent	titrations	
±	SDs,	except	values	from	Worrall	and	Mason	(2011)	 indicated	with	an	asterisk	and	values	
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for	 20-TAT48-57	 and	 20-NLS-TAT48-57	 (single	 titrations	 and	 fitting	 errors).	 CD	 and	 ITC	 data	
generally	agree	to	within	15	%	for	ΔG	and	an	order	of	magnitude	for	Kd.	ITC	experiments	not	
performed	 because	 binding	 measured	 by	 CD	 was	 negligible	 are	 labelled	 “ND”	 (“not	
determined”).	CD	or	 ITC	experiments	 that	generated	binding	 too	weak	 for	accurate	 fitting	
are	labelled	“NF”	(“not	fit”).		
	
	
	
	 	
1	
Complex	
Tm	(°C)	
(CD)	
Peptide–cJun	
Fractional	
Helicity	(%)	
(CD)	
Kd(20°C)	
(nM)	
(CD)	
∆G(20°C)	
(kcal/mol)	
(CD)	
Kd(20°C)	
(nM)	
(ITC)	
N	interaction	
stoichiometry	(ITC)	
∆G(20°C)	
(kcal/mol)	
(ITC)	
∆H(20°C)	
(kcal/mol)				
(ITC)	
T∆S(20°C)	
(kcal/mol)	
(ITC)	
Peptide–cJun	
Ɵ222/208	
(20°C)	(CD)	
cFos–cJun*	 16	 28	 320,000	 -5.5	 27,000	 1.1	±	0.01	 -6.1	±	0.39	 -0.82	±	0.36	 5.3	±	0.53	 0.75	
FosW–cJun	 63	 37	 4.0	 -11	 39	±	11	 0.99	±	0.08	 -9.9	±	0.16	 -10	±	0.42	 -0.46	±	0.46	 1.0	
1–cJun	 65	 44	 0.51	 -13	 9.6	±	5.7	 0.92	±	0.42	 -11	±	0.35	 -12	±	0.62	 -1.1	±	0.67	 0.98	
2–cJun	 60	 62	 19	 -10	 16	±	4.7	 0.95	±	0.03	 -10	±	0.17	 -13	±	0.30	 -3.0	±	0.41	 1.0	
3–cJun	 NF	 29	 NF	 NF	 ND	 ND	 ND	 ND	 ND	 0.70	
4–cJun	 63	 60	 33	 -10	 40	±	11	 0.86	±	0.10	 -9.9	±	0.16	 -14	±	0.33	 -3.9	±	0.44	 1.0	
5–cJun	 67	 74	 2.8	 -12	 29	±	19	 1.1	±	0.25	 -10	±	0.39	 -13	±	0.80	 -2.6	±	1.4	 1.1	
6–cJun	 66	 56	 2.4	 -12	 19	±	6.6	 0.57	±	0.01	 -10	±	0.20	 -16	±	1.0	 -6.0	±	1.1	 1.0	
7–cJun	 71	 73	 3.0	 -11	 8.6	±	1.8	 0.99	±	0.01	 -11	±	0.12	 -14	±	1.1	 -2.8	±	1.2	 1.1	
8–cJun	 71	 75	 0.54	 -12	 9.9	±	4.0	 0.77	±	0.14	 -11	±	0.23	 -12	±	1.5	 -1.5	±	1.6	 1.0	
9–cJun	 68	 77	 1.6	 -12	 11	±	5.5	 0.60	±	0.11	 -11	±	0.30	 -14	±	1.5	 -2.9	±	1.7	 1.0	
10–cJun	 NF	 34	 NF	 NF	 ND	 ND	 ND	 ND	 ND	 0.82	
11–cJun	 NF	 14	 NF	 NF	 ND	 ND	 ND	 ND	 ND	 0.61	
12–cJun	 NF	 25	 NF	 NF	 ND	 ND	 ND	 ND	 ND	 0.78	
13–cJun	 NF	 27	 NF	 NF	 ND	 ND	 ND	 ND	 ND	 0.79	
14–cJun	 44	 44	 1100	 -8.0	 2200	±	450	 0.75	±	0.29	 -7.6	±	0.12	 -13	±	1.0	 -5.7	±	1.0	 0.97	
15–cJun	 48	 62	 1100	 -8.0	 1000	±	560	 0.48	±	0.15	 -8.0	±	0.32	 -13	±	0.85	 -5.2	±	1.1	 1.0	
16–cJun	 38	 49	 6000	 -7.0	 ND	 ND	 ND	 ND	 ND	 1.0	
17–cJun	 19	 44	 100,000	 -5.4	 ND	 ND	 ND	 ND	 ND	 0.85	
18–cJun	 60	 69	 18	 -10	 56	±	14	 0.71	±	0.04	 -9.7	±	0.15	 -14	±	0.35	 -4.0	±	0.36	 1.0	
19–cJun	 63	 60	 8.3	 -11	 110	±	50	 0.62	±	0.12	 -9.4	±	0.28	 -10	±	0.54	 -1.1	±	0.53	 0.98	
20–cJun	 47	 62	 2000	 -7.7	 2000	±	420	 0.67	±	0.08	 -7.6	±	0.12	 -4.9	±	0.37	 2.8	±	0.40	 0.99	
LIN20–cJun	 NF	 39	 NF	 NF	 55,000	±	9700	 1.4	±	0.07	 -5.7	±	0.10	 -6.0	±	0.38	 -0.25	±	0.38	 0.81	
LIN20-TAT48-57–cJun	 42	 59	 3500	 -7.3	 ND	 ND	 ND	 ND	 ND	 0.91	
Pal-20–cJun	 NF	 28	 NF	 NF	 ND	 ND	 ND	 ND	 ND	 0.82	
20-TAT48-57–cJun	 53	 70	 1100	 -8.0	 5600	±	380	 1.1	±	0.01	 -7.1	±	0.04	 -5.3	±	0.05	 1.8	±	0.06	 0.95	
20-NLS-TAT48-57–cJun	 43	 39	 3100	 -7.4	 7600	±	460	 0.59	±	0.00	 -6.9	±	0.04	 -5.5	±	0.06	 1.3	±	0.07	 0.79	
NLS-TAT48-57–cJun	 NF	 11	 NF	 NF	 NF	 NF	 NF	 NF	 NF	 0.33	
18HC–cJun	 48	 44	 69	 -9.6	 320	±	50	 0.70	±	0.01	 -8.7	±	0.09	 -6.6	±	0.40	 2.1	±	0.50	 0.89	
20HC–cJun	 33	 35	 3300	 -7.4	 15,000	±	2400	 1.1	±	0.23	 -6.5	±	0.09	 -4.5	±	0.40	 2.0	±	0.41	 0.81	
abcdefg abcdefg abcdefg abcdefg abcd 
LDELQAE IEQLEER NYALRKE IEDLQKQ LEKL FosW 
|  |    |  |    |  |    |  |    |  | 
IARLEEK VKTLKAQ NYELAST ANMLREQ VAQL cJun	
FosW: ASLDELQAE IEQLEER NYALRKE IEDLQKQ LEKLGAP             N/A         39 ± 11      41         37 
1    Ac-LDELQAE IEQLEER NYALRKE IEDLQKQ LEDL-NH2          NΔ2 CΔ3      9.6 ± 5.7     44         44 
2    Ac-LDELQAE IEQLEER NYALRKE IKDLQDQ LEKL-NH2          NΔ2 CΔ3       16 ± 4.7     62         62 
3    Ac-LDELQAE IEQLEER NKALRDE IEDLQKQ LEKL-NH2          NΔ2 CΔ3         ND         40         29 
4    Ac-LDELQAE IKQLEDR NYALRKE IEDLQKQ LEKL-NH2          NΔ2 CΔ3       40 ± 11      59         60 
5    Ac-LKELQDE IEQLEER NYALRKE IEDLQKQ LEKL-NH2          NΔ2 CΔ3       29 ± 19      79         74 
6    Ac-LDELQAE IEQLEER NYALRKE IEDLQKQ LEDL-NH2          NΔ2 CΔ3       19 ± 6.6     53         56 
7    Ac-LDELQAE IEQLEKR NYDLRKE IEDLQKQ LEDL-NH2          NΔ2 CΔ3      8.6 ± 1.8     85         73 
8    Ac-LDELQKE IEDLEER NYALRKE IEDLQKQ LEDL-NH2          NΔ2 CΔ3      9.9 ± 4.0     78         75  
9    Ac-LKELQDE IEQLEER NYALRKE IEDLQKQ LEDL-NH2          NΔ2 CΔ3       11 ± 5.5     82         77 
10              Ac-LEKR NYDLRKE IEDLQKQ LEDL-NH2          NΔ12 CΔ3        ND         64         34 
11              Ac-LEKR NYDLRKE IEDLQKQ LEDL-NH2          NΔ12 CΔ3        ND         17         14 
12      Ac-LQKE IEDLEER NYALRKE IEDL-NH2                  NΔ5 CΔ10        ND         28         25 
13      Ac-LQKE IEDLEKR NYDLRKE IEDL-NH2                  NΔ5 CΔ10        ND         38         27 
14   Ac-LKELQDE IEQLEER NYALRKE IEDL-NH2                  NΔ2 CΔ10    2200 ± 450     39         44 
15   Ac-LKELQDE IEQLEKR NYDLRKE IEDL-NH2                  NΔ2 CΔ10    1000 ± 560     65         62 
16   Ac-LDELQAE IEQLEKR NYDLRKE IEDL-NH2                  NΔ2 CΔ10        ND         48         49 
17           Ac-IEQLEKR NYDLRKE IEDLQKQ L-NH2             NΔ9 CΔ6         ND         67         44 
18      Ac-LKAE IDQLEER NYALRKE IEDLQKQ LEDL-NH2          NΔ5 CΔ3       56 ± 14      72         69 
19      Ac-LQAE IKQLEDR NYALRKE IEDLQKQ LEDL-NH2          NΔ5 CΔ3      110 ± 50      64         60 
20           Ac-IKQLEDR NYALRKE IEDLQKQ LEDL-NH2          NΔ9 CΔ3     2000 ± 420     85         62 
LIN20        Ac-IKQLEDR NYALRKE IEDLQKQ LEDL-NH2          NΔ9 CΔ3   55,000 ± 9700    50         39 
LIN20-TAT48-57 Ac-IKQLEDR NYALRKE IEDLQKQ LEDL RKKRRQRRR-NH2     NΔ9 CΔ3         ND       66         59 
Pal-20      Pal-IKQLEDR NYALRKE IEDLQKQ LEDL-NH2          NΔ9 CΔ3         ND         28         28 
20-TAT48-57    Ac-IKQLEDR NYALRKE IEDLQKQ LEDL RKKRRQRRR-NH2   					NΔ9 CΔ3     5600 ± 380     96         70 
20-NLS-TAT48-57Ac-IKQLEDR NYALRKE IEDLQKQ LEDL PKKKRKVYGRKKRRQRRR-NH2			NΔ9 CΔ3     7600 ± 460     46         39 
NLS-TAT48-57       Ac-PKKKRKVYGRKKRRQRRR-NH2   N/A           NF          0         11   
18HC    Ac-LXAE IXQLEER NYALRKE IEDLQXQ LEXL-NH2      NΔ9 CΔ3      320 ± 50      40         44  
20HC    Ac-IXQLEXR NYALRKE IEDLQXQ LEXL-NH2      NΔ9 CΔ3   15,000 ± 2400    49         35 
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